ReviewBJUI compass2025
New insights into interstitial cystitis/bladder pain syndrome at single-cell resolution.
Review in BJUI compass, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Urinary Biomarkers in Interstitial Cystitis and Bladder Pain Syndrome: A Narrative Review of Differential Diagnosis and Treatment Monitoring.International urogynecology journal · 2026Review
- Diagnostic Model Development for IC/BPS and Its Subtypes Using Clinical Indicators, Urinary Biomarkers, and Single-Cell Transcriptomic Analysis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Review
- Benign Uroandrological Ecosystem: A Thorough Overview from Single-Cell and Spatial Transcriptomics.Research (Washington, D.C.) · 2026Review
- New insights into interstitial cystitis/bladder pain syndrome at single-cell resolution.BJUI compass · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic inflammatory bladder disorder with unknown aetiology and limited treatment options. Single-cell RNA-sequencing (scRNA-seq) has provided unprecedented insights into cellular heterogeneity in IC/BPS. This review summarizes recent scRNA-seq findings on bladder cell populations, emphasizing urothelial, interstitial and immune cells. Methods: A comprehensive analysis of published scRNA-seq studies was conducted to compare bladder cell subtypes in healthy and IC/BPS-affected bladders. Differences between IC/BPS patients and mouse models, as well as sex-specific cellular variations, were examined. Results: IC/BPS bladders exhibit significant urothelial alterations, including a reduction in UPK3A + umbrella cells and an expansion of progenitor-like cells with impaired regenerative capacity, linked to TLR3-NR2F6 signalling. Interstitial cells include three fibroblast subtypes (PDGFRA+, RGS5+ and pro-inflammatory IL6-producing fibroblasts), which contribute to fibrosis and inflammation. The immune landscape is characterized by a Th1-biased response, exhausted CD8 + T cells and reduced regulatory T cells, with HPV infection detected in most IC/BPS patients, suggesting a possible viral aetiology. Cell-to-cell interactions are compromised, with enhanced macrophage-endothelial signalling via CXCL8-ACKR1 and CXCL2/3-ACKR1 pathways, highlighting potential therapeutic targets. Notably, sex-based differences reveal stronger immune activation in females and increased urothelial proliferation in males, potentially explaining the higher IC/BPS prevalence in females. Conclusions: scRNA-seq has advanced our understanding of IC/BPS by identifying disease-associated cell types, signalling pathways and intercellular interactions. Future research should integrate multi-omics approaches and explore non-invasive urine-based scRNA-seq for improved diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.